Press release from Business Wire
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2013 Financial Results on November 5, 2013
Tuesday, October 15, 2013
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2013 Financial Results on November 5, 201309:00 EDT Tuesday, October 15, 2013
BOTHELL, Wash. (Business Wire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2013 financial results on Tuesday, November 5, 2013, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Tuesday, November 5, 2013
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
- Telephone 866-225-8754 (domestic) or 480-629-9818 (international); conference ID 4645309
- Webcast available at www.seattlegenetics.com/ in the Investors and News section
- Telephone replay will be available beginning at approximately 3:30 p.m. PT on Tuesday, November 5, 2013 through 5:00 p.m. PT on Thursday, November 7, 2013 by calling 800-406-7325 (domestic) or 303-590-3030 (international); conference ID 4645309
- Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com/ in the Investors and News section
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS® (brentuximab vedotin), is an ADC that, in collaboration with Millennium: the Takeda Oncology Company, has been approved for two indications in 35 countries, including the U.S., European Union and Canada. Additionally, ADCETRIS is being evaluated broadly in more than 20 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-75, ASG-22ME, SGN-CD19A, SGN-CD33A, SGN-LIV1A and ASG-15ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160